Hyperkeratosis

Verify with FDA CVM →

VeDDRA Code: 896

162 adverse event reports referencing this reaction

162
Total Reports
17
Deaths
1050.0%
Death Rate

Species Most Affected

Dog 143
Cat 12
Mouse 4
Cattle 2
Horse 1

Breeds Most Affected

Retriever - Labrador 11
Retriever - Golden 9
Domestic Shorthair 9
Crossbred Canine/dog 7
Shepherd Dog - German 6
Dog (unknown) 6
Unknown 5
Chihuahua 5
Boxer (German Boxer) 4
Schnauzer (unspecified) 4

Associated Drugs

Oclacitinib Maleate 32
Cyclosporine A 24
Cyclosporine 19
Trilostane 18
Milbemycin Oxime + Spinosad 12
Maropitant Citrate 11
Prednisone 10
Afoxolaner 10
Enrofloxacin 9
Cefpodoxime Proxetil 8
Metronidazole 7
Anti-Il31 Mab Mcs Lot #1283563 7
Cefovecin Sodium 6
Ketoconazole 6
Prednisolone 6
Pentoxifylline 6
Hydrolyzed Protein Diet 6
Fluralaner Chew Tablets 5
Gabapentin 5
Carprofen 4

Data Summary

Metric Value
Total reports referencing reaction 162
Reports with fatal outcome 17
Case-fatality rate (reported events) 1050.0%
Species observed 5
Breeds observed 20
Drugs associated with reaction 20

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER); reaction term coded under VeDDRA 896.

Hyperkeratosis Reaction Insights

The FDA Center for Veterinary Medicine database currently lists 162 adverse event reports that reference Hyperkeratosis as a reaction term, including 17 reports with a death outcome — a 1050.0% case-fatality figure calculated across only those events where this reaction was coded. The reaction is indexed in the openFDA system under VeDDRA code 896, the standardized veterinary dictionary used to normalize clinical signs across submitters. Because reports are voluntary and often describe multiple concurrent signs per animal, the volume here reflects reporting intensity rather than true incidence in the broader pet population.

Hyperkeratosis appears most frequently in reports for Dog (143 reports), Cat (12 reports), Mouse (4 reports) — with Dog dominating at 143 entries. Within those species, the breeds most often named alongside this reaction are Retriever - Labrador (11), Retriever - Golden (9), Domestic Shorthair (9). These distributions are influenced both by underlying breed popularity and by how veterinarians and owners code a given clinical sign, so they should be interpreted as a reporting fingerprint rather than a pure susceptibility ranking.

The drugs most commonly co-reported with Hyperkeratosis are Oclacitinib Maleate (32 reports), Cyclosporine A (24 reports), Cyclosporine (19 reports), Trilostane (18 reports), with Oclacitinib Maleate appearing alongside this reaction in 32 submissions. Co-reporting does not establish that any specific product caused the reaction — FDA CVM data captures temporal association only. The value of these aggregates is in flagging which therapeutic classes appear repeatedly alongside a given clinical sign, so owners and veterinarians can ask targeted questions about medications currently in use.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial